New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus
Executive Summary
Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.